Literature DB >> 12080289

Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users.

H J Stuerenburg1, K Petersen, T Bäumer, M Rosenkranz, C Buhmann, R Thomasius.   

Abstract

Recreational use of the synthetic methamphetamine derivative MDMA (3,4-methylenedioxymethamphetamine), the main constituent of the illegal drug "ecstasy", has increased dramatically in recent years. The reasons for ecstasy-associated cardiovascular complications like tachycardia, arrhythmias and hypertensive crises and psychiatric symptoms like psychotic episodes are not well understood. We have measured the plasma concentrations of 5-HIAA, 5-HT, norepinephrine, epinephrine and dopamine in 159 ecstasy users and controls. Ecstasy users showed elevated resting sympathetic activity, reflected in increased norepinephrine, epinephrine and dopamine levels. The levels of these catecholamines correlated positively with the cumulative dose and also with consumption during the last 30 days and 12 months. Although it is known that significant changes in 5-HT and 5-HIAA appear in the cerebrospinal fluid in ecstasy users, we could not detect alterations in serotonergic neurotransmitters in plasma in this large sample of subjects. Thus, in the drug-free interval, ecstasy users show lowered central serotonergic activity (lowered 5-HT and 5-HIAA concentrations in CSF) along with unchanged central noradrenergic and dopaminergic activity (HVA and MHPG unchanged in CSF) and elevated peripheral noradrenergic, dopaminergic and adrenergic activity along with unchanged peripheral serotonergic activity (plasma levels). We conclude, that the data presented here could argue for a noradrenergic hyperreactivity in the drug-free interval in ecstasy users resulting from previous ecstasy consumption. Also for an association with psychotic episodes and cardiovascular complications like tachycardia, arrhythmias.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12080289

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  15 in total

1.  Role of Macrophage Dopamine Receptors in Mediating Cytokine Production: Implications for Neuroinflammation in the Context of HIV-Associated Neurocognitive Disorders.

Authors:  R A Nolan; R Muir; K Runner; E K Haddad; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2018-12-05       Impact factor: 4.147

Review 2.  The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives.

Authors:  J R Docherty; A R Green
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

3.  Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA ("Ecstasy").

Authors:  Boris B Quednow; Kai-Uwe Kühn; Christian Hoppe; Jens Westheide; Wolfgang Maier; Irene Daum; Michael Wagner
Journal:  Psychopharmacology (Berl)       Date:  2006-01-20       Impact factor: 4.530

4.  Perceived risk associated with ecstasy use: a latent class analysis approach.

Authors:  S S Martins; R G Carlson; P K Alexandre; R S Falck
Journal:  Addict Behav       Date:  2011-01-20       Impact factor: 3.913

Review 5.  The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine.

Authors:  Edward M Mills; Daniel E Rusyniak; Jon E Sprague
Journal:  J Mol Med (Berl)       Date:  2004-11-10       Impact factor: 4.599

6.  Effects of acute 3,4-methylenedioxymethamphetamine on sleep and daytime sleepiness in MDMA users: a preliminary study.

Authors:  Surilla Randall; Chris-Ellyn Johanson; Manuel Tancer; Timothy Roehrs
Journal:  Sleep       Date:  2009-11       Impact factor: 5.849

Review 7.  Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): a stressor on the immune system.

Authors:  Thomas J Connor
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

8.  Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-adrenoceptors.

Authors:  Sotiria Bexis; James R Docherty
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

9.  MDMA (N-methyl-3,4-methylenedioxyamphetamine) and its stereoisomers: Similarities and differences in behavioral effects in an automated activity apparatus in mice.

Authors:  Richard Young; Richard A Glennon
Journal:  Pharmacol Biochem Behav       Date:  2007-09-14       Impact factor: 3.533

10.  MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat.

Authors:  Kelly J Clemens; Petra S Van Nieuwenhuyzen; Kong M Li; Jennifer L Cornish; Glenn E Hunt; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2004-03-17       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.